Global Lung Cancer Therapeutics Market By Therapy (Targeted, Therapy, Immunotherapy, Radiation Therapy, Chemotherapy, and Other Therapies), by Cancer Type (Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Lung Carcinoid Tumor), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Other Distribution Channels), And Regional Forecast 2023-2032

Report Overview

In 2022, The Global Lung Cancer Therapeutics Market was valued at USD 28.9 Billion in 2023, it is estimated to reach USD 76.5 Billion in 2032, and this market is estimated to register the highest CAGR of 10.5%.

Lung cancer is one of the varieties of cancer made in the lung tissues. It is otherwise called pulmonary carcinoma and is organized by clamorous development in the lung tissues.

The significant symptoms of lung cancer include wheezing, coughing, chest torment, weight reduction, and bodily fluids, shortness of breath, and hunger loss. The various therapies accessible for lung cancer include radiation therapy, surgery, immunization therapy, immunotherapy, and chemotherapy. The leading reason for lung cancer is continued exposure to asbestos, cigarette smoking, pipe smoking, and stogie smoking.

The global lung cancer therapeutics market is supposed to grow at a high rate because of the growing number of people experiencing lung cancer. There is a critical requirement for therapy and diagnosis for the high-level phases of lung cancer. The potential drivers for the global lung cancer therapeutics market contain the rising geriatric population, increasing smoking of tobacco which includes latent smoking, and changing lifestyles of people.

Furthermore, factors, for example, targeted and ground-breaking delivery of drugs to the lung coupled with a rising acknowledgment of personalized therapies, are also essential factors driving the all-around demand for lung cancer therapeutics.

However, the limited options for therapy, and the monstrous availability of the nonexclusive type of essential drugs, are significant factors influencing the growth of the overall lung cancer therapeutics market. Additionally, radiation therapy and chemotherapies pose an immense test to unfavorable effects. Subsequently, the major players in the market are expected to focus on more secure therapeutics and high-level therapy.

Even though new medications have vitalized the global lung cancer therapeutics market, the expiry of licenses on the ongoing drugs may also negatively influence the demand. As the cost of formulating the drugs is rising, it has forced drug producers to diminish their interests in research and development.

Driving Factors

Rising geriatric population and high prevalence of lung cancer

The worldwide lung cancer therapeutics market is supposed to have a high growth rate because of the developing number of individuals experiencing lung cancer. There is a critical requirement for therapy and symptomatic for the high-level phases of lung cancer. The likely drivers for the worldwide lung cancer therapeutics market incorporate expanding geriatric populace, changing way of life of individuals, and increasing smoking of tobacco, including inactive smoking.

Moreover, factors, for example, targeted and weighty conveyance of drugs to the lung combined with a rising acknowledgment of customized therapies are also seen to be a significant element driving the general lung cancer therapeutics market.

Cancer is a gene-related infection that cells develop unusually during the change. These cells stream from the first site to different locales via blood and lymph. Lung cancer creates challenges in providing oxygen to the blood. Lung cancer has the most noteworthy mortality rate among both the male and female populace and most lung cancer is non-small cell lung cancer. Lung cancer is the considerable predominant sort of cancer across the world, and it influences the lung tissues.

The worldwide lung cancer therapeutics marketplace is expected to observe a huge growth inferable from the flooding pervasiveness of lung cancer among the worldwide populace. About 19.3 million fresh instances of cancer were kept in 2020, and about 11.3% of it was lung cancer. Lung cancer was the main source of death, with around 18%. The frequencies of lung cancer are developing quickly across the globe, inferable from the rising predominance of smoking and openness to recycled smoke.

Restraining Factors

The adverse effects of chemotherapies and the lack of poor cancer diagnostic facilities in many countries are expected to obstruct market growth. Also, stringent regulations are projected to challenge the market over the forecasted time period.

Moreover, radiation therapy and chemotherapies represent a tremendous test to unfavorable impacts. Thus, the key players in the market are expected to fixate their consideration on more secure therapeutics and high-level therapy. Also, even though new drugs have stimulated the market, the expiry of licenses on the ongoing drugs may likewise adversely affect the market.

As the expense of fostering the drugs is expanding, it has constrained the drug producers to decrease their interest in research and improvement. Lastly, a deficiency of talented staff, absence of specialized skills to deal with the constant applications, and absence of normalization further repress the market’s growth.

COVID-19 Impact Analysis

The COVID-19 episode has disturbed the psychological and actual well-being of patients with lung cancer. In addition, lung cancer patients are at a higher gamble for this irresistible illness. During the lockdown limitations, the specialists treated just the crisis cases, while the excess therapy or conclusion for the cancer was deferred. With the slight unwinding by the public authority worldwide, the interest in the market floods consistently.

As COVID-19 is going after serious lung cancer individuals, hospitals determine how to pay extreme attention to detail. Notwithstanding, attributable to the diminishing number of COVID-19 cases, the therapy methodology for lung cancer patients is supposed to get grow.

The clinical benefits, for example, lung cancer therapeutics, saw a decrease in incomes in the years 2020 and 2021 because of the flare-up of COVID-19. Significant operations were declined during the pandemic to forestall the gamble of spreading COVID. In any case, ascend in lung cancer therapeutics strategies is normal in the post-COVID attributable to the facilitating of limitations.

By Therapy Type Analysis

The targeted therapy segment holds a major share of 45% in the market. Targeted therapy has gained attention in the treatment of lung cancer. The rising research and improvement costs and speedy growth of the biopharmaceutical sector have achieved the advancement of state-of-the-art targeted therapeutics in treating lung cancer. The targeted therapy can actually feast on the cancer cells without changing the ordinary cells of the body. This result is unimportant auxiliary impacts and disposes of the potential outcomes of reoccurrence and passing.

Immunotherapy is expected to grow at a high rate during the forecast period. Immunotherapy utilizes the resistance framework to dispense with, forestall, and control the cancer-inducing cells in the body. It improves the safe framework and teaches the insusceptible framework to distinguish the cancer cells and assault those particular cells to treat lung cancer. Immunotherapy is viewed as a savvy method for forestalling cancer cells and it is quickly building up some momentum among cancer patients. Hence, immunotherapy is anticipated to witness high growth in the market.

By Cancer Type Analysis

The non-small cell lung cancer ruled the market during the projected time period. This growth is basically ascribed to the expanded commonness of non-small cell lung cancer among the populace. The therapy of non-small cell lung cancer thoroughly relies upon the phases of this cancer. It is assessed that around 80% of lung cancer are non-small cell lung cancer and consequently, the interest in lung cancer therapeutics to fix this kind of lung cancer has moved the growth of this section in the worldwide lung cancer therapeutics market.

Small cell lung cancer is projected to witness high growth due to the pervasiveness of smoking and the rising incidence of small cell lung cancer (SCLC). The rising mindfulness in patients with respect to small cell lung cancer (SCLC) and the accessibility of betterment therapeutics stimulates segment growth.

Distribution Channel Analysis

In view of the distribution channel, hospital pharmacies ruled the market in 2022. The expanded volume of patient affirmations in hospitals for getting the therapy and conclusion of cancer has altogether supported the deals of lung cancer therapeutics from hospital drug stores across the globe. Besides, the expanded inclination among customers to purchase drugs from hospital drug stores attributable to the accessibility of a colossal assortment of drugs has brought about the predominance of this segment.

Online pharmacies are likely to experience high growth during the forecast period. The rising infiltration of computerized media and further developing admittance to the web has helped online businesses. The quick rise of the online pharmacies section has acquired ubiquity among clients attributable to the straightforwardness and accommodations related to online pharmacies.

Key Market Segments

By Therapy

• Targeted Therapy
• Bevacizumab
• Dabrafenib/Trametinib
• Erlotinib Hydrochloride
• Osimertinib
• Others
• Immunotherapy
• Durvalumab
• Nivolumab
• Atezolizumab
• Pembrolizumab
• Chemotherapy

By Cancer Type

• Non-small cell lung cancer (NSCLC)
• Small cell lung cancer (SCLC)

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Channels

Opportunity

Development of New Therapies and R&D Initiatives

In 2022, an expected 236,740 Americans were probably going to get a lung cancer determination, as per the American Cancer Society. 130,180 of those were expected to die. Furthermore, it is extended that the sendoff of costly new drugs and novel refined radiation therapies will speed up market expansion. Later on, market members may likewise have advancement potential because of novel and more secure therapies. Lung cancer therapeutics market growth is expected because of state-run administrations’ rising endeavors and ventures to construct medical care foundations and give great therapy choices. What’s more, one of the key drivers helping market extension is individuals’ rising comprehension of the numerous lung cancer therapeutics choices. Moreover, factors like rising extra cash, progressing research and improvement to make new advancements, the presentation of the latest radiation therapy innovation, and the extending economies in creating and immature countries are expected to incline toward the market’s growth rate throughout the forecast period. Subsequently, this component is driving the market CAGR.

Trends

Growing Demand for Targeted Therapies and New Collaborations

A developing pattern in the lung cancer therapeutics market is the utilization of targeted medicine therapy related to extra therapies. To support the early identification, counteraction, and treatment of the illness, immunotherapy prescriptions are utilized in a mix of different treatments, including chemotherapy. Drug organizations are making targeted prescription regimens to successfully analyze and treat lung cancer. For example, Pembrolizumab, a medicine made by Merck and Co., helps the safe framework in distinguishing and wiping out cancer cells when utilized with chemotherapy. The patients’ lung cancer status worked on because of this joined treatment. The drug is showcased as Keytruda and is a critical contribution from Merck and Co.

Rise in essential collaborations contributes to market growth. The quantity of vital coordinated efforts for the turn of events and commercialization of drugs for the treatment of both NSCLC and SCLC has essentially expanded on the lookout. To co-develop and co-popularize M7824, a bi-functional combination protein immunotherapy, for the treatment of NSCLC, GlaxoSmithKline Plc. Moreover, Merck and Co. Inc. worked together in February 2019. The sendoff of modern medications is expected to result for the rising number of merchant key coalitions, filling the market’s development over the forecast period. Along these lines, it is guessed that this angle will speed up lung cancer therapeutics market income internationally.

Regional Analysis

North America leads the market by holding a major revenue share in the account.

North America ruled the worldwide lung cancer therapeutics market throughout recent years. The popularity in the district was supported by factors that incorporate expanding events of lung cancer and rising degrees of the geriatric populace. Alongside it, the changing ways of life with high smoking propensities, which lead to an immense pool of carcinoma lung populace, is likewise liable for the monstrous occurrences of lung cancer in North America.

Asia-Pacific is expected to witness high growth rate in the market. This colossal growth is normal by virtue of developing mindfulness concerning improved medical services and the presence of clinical requirements for cancer therapeutics in the emerging economies of China and India, which are yet undiscovered. Most of the income in Asia Pacific will be generated by the rising countries of India and China attributable to the expansion in the smoking populace and individuals impacted by lung cancer.

Key Regions and Countries

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • Spain
  • Rest of Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Rest of Asia-Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• MEA
  • GCC
  • South Africa
  • Israel
  • Rest of MEA

Key Players Analysis

The lung cancer therapeutics market competitive landscape gives nuances by competitors. Nuances contained are market potential, premium in research and progression, overall presence, new market players, etc. The market is reasonably competitive and fragmented. Key players are focusing on new partnerships and collaborations to increase their presence in the market.

Top Key Players

• Merck & Co., Inc.,
• Roche Ltd
• Boehringer Ingelheim International GmbH
• Sun Pharmaceutical Industries Ltd.
• Amgen Inc.
• Allergan Inc.
• Adorx Therapeutics Limited
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson Innovation LLC
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Other Key Players

Recent Development

• In September 2019, Tagrisso, an EGFR tyrosine kinase inhibitor, received marketing approval from China’s National Medical Products Administration (NMPA). This medicine treats patients with EGFR-mutated non-small cell lung cancer (NSCL). The approval has restricted Chinese corporations from promoting and commercializing medicines and increasing the business.
• In March 2019, Adorx Therapeutics declared that it had gone into long haul points and interests of the organization with Johnson and Johnson Advancement LLC and Lung Cancer Drive at Johnson and Johnson (LCI) of new original lung cancer therapeutics.

Report Scope